CN115518133B - Traditional Chinese veterinary medicine composition for treating cat stranguria - Google Patents

Traditional Chinese veterinary medicine composition for treating cat stranguria Download PDF

Info

Publication number
CN115518133B
CN115518133B CN202211326301.4A CN202211326301A CN115518133B CN 115518133 B CN115518133 B CN 115518133B CN 202211326301 A CN202211326301 A CN 202211326301A CN 115518133 B CN115518133 B CN 115518133B
Authority
CN
China
Prior art keywords
traditional chinese
powder
wall breaking
low temperature
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211326301.4A
Other languages
Chinese (zh)
Other versions
CN115518133A (en
Inventor
王帅玉
何成蹊
李格宾
范开
董彦君
刘天龙
郝智慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Agricultural University
Original Assignee
China Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Agricultural University filed Critical China Agricultural University
Priority to CN202211326301.4A priority Critical patent/CN115518133B/en
Publication of CN115518133A publication Critical patent/CN115518133A/en
Application granted granted Critical
Publication of CN115518133B publication Critical patent/CN115518133B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
    • A61K36/835—Aquilaria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a traditional Chinese veterinary medicine composition for treating cat stranguria, which is mainly prepared from six raw materials including pyrrosia lingua, plantain seed, lophatherum gracile, agilawood, white paeony root and honey-fried licorice root. The medicine has the effects of clearing heat and promoting diuresis, inducing diuresis for treating stranguria, softening liver and nourishing yin, promoting qi circulation and relieving pain. The pharmacodynamics research results show that the medicine has good anti-inflammatory, analgesic and diuretic effects.

Description

Traditional Chinese veterinary medicine composition for treating cat stranguria
Technical Field
The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese veterinary medicine composition for treating cat stranguria and a preparation method thereof.
Background
Suburinary tract syndrome (feline lower urinary tract disease, flute) is a common disease in cats, severely affecting the quality of life and health of the cats. It is counted that 3% -5% of cats to the pet hospital visit are due to flute, and about 30% -70% of cats with flute relapse. Flute is a generic term for a series of heterogeneous lower urinary tract diseases with similar clinical symptoms, and the main clinical symptoms of suffering cats include dysuria, urination pain, frequent urination, dribbling, ectopic urination, etc., and flute can be mainly classified into cat idiopathic cystitis (feline idiopathic cystitis, FIC), bacterial urinary tract infection, urinary tract stones, urinary tract emboli, anatomical abnormality of urinary system, tumor, etc. Among them, the most suffering cats diagnosed with FIC account for 55% -65% of all flute cases. Several studies have shown that cats under 10 years of age, particularly cats from 2 to 7 years of age, are more susceptible to FIC. In addition, factors such as overweight, low activity, living in multi-cat households, inadequate drinking, etc., may be related to the FIC. The etiology of FIC is complex and ambiguous, and many studies suggest that FIC may be associated with abnormalities in the neuroendocrine system caused by cats suffering from various stresses. Recently, the literature has proposed replacing cat idiopathic cystitis with the new term "pandura syndrome" with the aim of avoiding misunderstandings from the use of specific organ naming and of greater concern for systemic multisystem complications associated therewith. Male cats are prone to urine closure due to narrow urethra, and if the male cats are not cured in time, uremia and acute renal failure are prone to occur, and finally the suffering cats die. Mortality in cats with flute is 6% -36%. In addition, because pet owners are reluctant to repeatedly pay expensive diagnostic, therapeutic and hospitalization costs for suffering cats with lower urinary tract symptoms and urinary obstruction, many cats with recurrent flute d are euthanized, which further increases mortality.
At present, there are no specific drugs for treating FIC clinically. In the acute onset of FIC, commonly used therapeutic agents include: antibiotics, anti-inflammatory, spasmolytic and analgesic drugs. However, antibiotics have proven ineffective in treating FIC, the nonsteroidal anti-inflammatory drug meloxicam was found ineffective in alleviating lower urinary tract symptoms in two clinical trials, and the spasmolytic drugs oxybutynin and propiverine, while capable of alleviating the frequent symptoms in some cats, random control studies showed that more than 70% of FIC cats were also effective with placebo (lactose, wheat flour), suggesting that there is not necessarily a causal relationship between medication and symptom improvement. In addition, to reduce the recurrence rate of FIC, or to extend the interval between FIC episodes, the tricyclic antidepressants amitriptyline and the mood-soothing agent feromone are recommended for long-term use to reduce stress in cats. In addition, mucopolysaccharides are recommended as bladder mucosal layer substitutes to repair the injured bladder mucosa of FIC cats. However, the effectiveness of these drugs has not been verified by clinical trials. Moreover, many drugs recommended for use in foreign literature have not been approved for use in pet clinic at home. In the domestic market, some health care products of cat urinary systems comprise algal sulfated polysaccharide, cranberry extract, compound vitamins and the like, but the effectiveness of the health care products is not verified by experiments, and most of the health care products are psychological placebo for pet owners. With the development of the pet industry in China, the number of cat raising groups is gradually increased, so that the number of the FLUTD suffering cats is increased, pain is brought to the suffering cats, and meanwhile, economic burden and mental stress are brought to the majority of pet owners. Therefore, the research of new drugs for treating FLUTD has a certain practical significance.
In traditional Chinese veterinary medicine, FLUTD belongs to the category of "stranguria", and therefore may be referred to as cat stranguria. The main causes of cat stranguria can be classified into damp-heat type, improper diet, emotional disorder, insufficient endowment or chronic diseases. Referring to the traditional Chinese medicine typing of stranguria, according to the pathogenesis, the cat stranguria can be classified into three types of stranguria caused by heat (damp-heat type bladder), stranguria caused by qi stagnation (liver depression and qi stagnation) and stranguria caused by fatigue (chronic stranguria), wherein the former two types of stranguria mainly belong to excess symptoms, and the stranguria caused by fatigue mainly belong to deficiency symptoms. The heat stranguria is caused by the long-term overfeeding of the cat with the paste Liang Houwei, insufficient drinking water and insufficient movement, which results in the internal generation of damp-heat, or by the injection of exogenous damp-heat evil into the lower-jiao. Most of the qi stranguria is that the existing pet cats are often confined indoors, the range of motion and enjoyed resources are limited, so that the pet cats cannot fully express the nature of the pet cats, and potential pressure sources in life, such as environment change, dissonance with other members of the family and the like, cause the sexually sensitive cats to feel anxiety and fear, and the cat liver qi in the environment for a long time is uncomfortable, and is stressed after being stimulated, so that qi stagnation and liver depression are easy to occur. The overstrain stranguria is caused by the deficiency of the vital energy due to the disunion of the chronic disease or repeated attacks of stranguria. Clinically common FIC suffering cats are more prone to stranguria in middle veterinarian typing due to the relevance of stress factors to FIC. In addition, cat stranguria can be classified into three kinds of stranguria with blood, stranguria with stone and stranguria with paste according to clinical symptoms, which are respectively manifested as blood in urine, fine sand and stone in urine, turbid urine and sticky urine. As described in "Jikui Yao Lloyd" the stranguria is a disease, urine is like millet, the lower abdomen is urgent, pain is induced in the umbilicus ", the primary stage of the onset of the stranguria with cats is mainly characterized by dribbling urine, frequent urination and painful urination. Later, if the disease condition further progresses, the blood collaterals are burned, and then blood stranguria occurs; the urine is decocted into stone by damp-heat, so that the stone stranguria can occur; when damp-heat is downward flowing, the urinary bladder cannot be cleared and turbid, such as rice swill or grease, there is stranguria. In addition, as described in "Yuan Heng Jiu Ma Ji" that "the cell channel is not passed through with qi" it is similar to Yongquan in terms of yin and yang, clear qi does not raise turbid qi and is closed, and accumulation and fullness are not passed through "like" it is said that if there is heat accumulation in the bladder, qi stagnation is unfavorable, and "the transformation" will occur in some stranguria-treating cats, namely, urine is closed.
The traditional Chinese medicine for treating stranguria has the advantages of safety, small toxic and side effects, obvious short-term and long-term curative effects, low price and the like. However, most traditional Chinese medicines are decoction decocted with water, and have the defects of inconvenient operation, poor taste, loss of active ingredients of the medicines, unfavorable popularization and the like. In the invention, pyrrosia lingua, plantain seed and lophatherum gracile have the effects of clearing heat and promoting diuresis and treating stranguria, and agilawood, white paeony root and honey-fried licorice root have the effects of promoting qi circulation and relieving pain, and nourishing liver and yin. The medicines are combined to treat both principal and secondary aspect of disease, strengthen body resistance and eliminate pathogenic factors, can avoid adverse reactions caused by western medicines, obviously improve curative effect and reduce recurrence rate. The invention aims to provide a veterinary drug composition for treating cat stranguria, which is convenient to take, can fully retain active ingredients of the drugs, has stable and controllable quality and can meet clinical requirements.
Disclosure of Invention
The traditional Chinese veterinary medicine composition with the effects of easing pain, resisting inflammation and promoting urination is prepared by combining clinical experience of a researcher under the guidance of a traditional Chinese veterinary medicine theory, referring to a modern pharmacological research result formula and carrying out pharmacodynamics research.
The invention aims to provide a veterinary drug composition for treating cat stranguria, which is convenient to take, can fully retain active ingredients of the drugs, has stable and controllable quality and can meet clinical requirements. It is another object of the present invention to provide a process for the preparation of the medicament.
The invention is realized by the following technical scheme:
the invention provides a traditional Chinese veterinary medicine composition for treating cat stranguria, which is mainly prepared from the following raw materials:
pyrrosia lingua 20 parts, plantain seed 20 parts and lophatherum gracile 20 parts
20 parts of agilawood, 20 parts of radix paeoniae alba and 20 parts of honey-fried licorice root
The preparation method of the veterinary drug composition provided by the invention is realized by the following technical scheme:
1) Drying folium Pyrrosiae at low temperature with microwave to remove water to water content below 5%, pulverizing with low temperature wall breaking machine to obtain superfine powder with cell wall breaking rate above 95% and powder particle diameter below 5 μm.
2) Taking semen plantaginis, drying at low temperature with microwave to remove water to make water content of Chinese medicinal materials below 5%, pulverizing with low temperature wall breaking machine to obtain superfine powder with cell wall breaking rate above 95% and powder particle diameter below 5 μm.
3) Taking lophatherum gracile, drying and dehydrating at low temperature by microwaves to ensure that the water content of the traditional Chinese medicine is below 5%, and pulverizing by a low-temperature wall breaking machine to obtain traditional Chinese medicine superfine powder with the cell wall breaking rate of above 95% and the powder particle diameter of below 5 mu m for standby.
4) Taking agilawood, drying and dehydrating at a low temperature by microwaves to ensure that the water content of the traditional Chinese medicine is below 5%, and pulverizing the traditional Chinese medicine into powder by a low-temperature wall breaking machine to ensure that the cell wall breaking rate is above 95%, wherein the particle size of the powder is below 5 mu m for standby.
5) Taking white peony root, drying and dehydrating at a low temperature by microwaves to ensure that the water content of the traditional Chinese medicine is below 5%, pulverizing the traditional Chinese medicine into powder by a low-temperature wall breaking machine to ensure that the cell wall breaking rate is above 95%, and obtaining the traditional Chinese medicine superfine powder with the powder particle size below 5 mu m for standby.
6) Drying radix Glycyrrhizae Preparata with microwave at low temperature, dehydrating to water content below 5%, pulverizing with low temperature wall breaking machine to obtain superfine powder with cell wall breaking rate above 95% and powder particle diameter below 5 μm.
7) Mixing the superfine powder of the six Chinese medicinal materials obtained in 1), 2), 3), 4), 5) and 6) to obtain the veterinary composition with analgesic, antiinflammatory and diuretic effects, and adding corresponding pharmaceutically acceptable carrier to obtain oral preparation.
The oral medicament can be any one of the pharmaceutical oral dosage forms.
The oral medicament comprises, but is not limited to, powder and capsules.
The oral powder can be prepared by the following method: taking 120 parts of the prepared traditional Chinese veterinary medicine composition, further grinding, stirring and uniformly mixing by a small electric pulverizer, dividing into 10 bags, wherein each bag contains 12 parts of the traditional Chinese veterinary medicine composition, and packaging by hot-pressing plastic package.
The oral capsule can be prepared by the following method: taking 300 parts of the prepared traditional Chinese veterinary medicine composition, further grinding, stirring and uniformly mixing by using a small electric pulverizer, using a 100-hole No. 0 capsule plate, averagely subpackaging the traditional Chinese veterinary medicine composition into 100 No. 0 capsule bodies, wherein each granule contains 3 parts of the traditional Chinese veterinary medicine composition, and covering a capsule cap.
The medicine has the effects of clearing heat and promoting diuresis, inducing diuresis for treating stranguria, softening liver and nourishing yin, promoting qi circulation and relieving pain, and has the effects of resisting inflammation, easing pain and promoting urination. The medicine of the invention is convenient to take, can fully retain the effective components of the medicine, has stable and controllable quality, no adverse reaction and obvious curative effect.
The invention will be further illustrated by means of specific examples and pharmacodynamic test results.
Detailed Description
The present invention is further described with reference to the following specific examples, which are not intended to be limiting, and embodiments of the present invention are not intended to be limited to the details shown, but rather are to be construed according to the present disclosure.
Example 1:
prescription:
pyrrosia lingua 2g plantain seed 2g lophatherum gracile 2g
Agilawood 2g white peony root 2g honey-fried licorice root 2g
Making into 10-bag powder
The preparation method comprises the following steps:
taking pyrrosia lingua, plantain seed, lophatherum gracile, agilawood, white paeony root and honey-fried licorice root according to a prescription, respectively carrying out microwave low-temperature drying and dehydration to ensure that the water content of the traditional Chinese medicine is below 5%, respectively pulverizing the traditional Chinese medicine by a low-temperature wall breaking machine to prepare traditional Chinese medicine superfine powder with the cell wall breaking rate of above 95% and the powder particle diameter of below 5 mu m, uniformly mixing to prepare the traditional Chinese medicine composition, further grinding, stirring and uniformly mixing the traditional Chinese medicine composition by a small electric grinding machine, uniformly dividing into 10 bags, each bag containing 1.2g of the traditional Chinese medicine composition, and carrying out hot-pressing plastic package.
Example 2:
prescription:
pyrrosia lingua 5g, plantain seed 5g and lophatherum gracile 5g
Agilawood 5g white peony root 5g honey-fried licorice root 5g
Making into 100 capsules
The preparation method comprises the following steps:
taking pyrrosia lingua, plantain seed, lophatherum gracile, agilawood, white paeony root and honey-fried licorice root according to a prescription, respectively carrying out microwave low-temperature drying and dehydration to ensure that the water content of traditional Chinese medicine is below 5%, respectively pulverizing by a low-temperature wall breaking machine to prepare traditional Chinese medicine superfine powder with the cell wall breaking rate of above 95% and the powder particle diameter of below 5 mu m, mixing uniformly to prepare the traditional Chinese medicine composition, further grinding, stirring and mixing uniformly by a small electric grinding machine, using a 100-hole 0-number capsule plate, evenly packaging the traditional Chinese medicine composition into 100-number 0 capsules, wherein each capsule contains 0.3g of the traditional Chinese medicine composition, and covering a capsule cap.
Example 3:
prescription:
pyrrosia lingua 1g plantain seed 1g lophatherum gracile 1g
Agilawood 1g white peony root 1g honey-fried licorice root 1g
Making into 0.2g/mL suspension
The preparation method comprises the following steps:
taking pyrrosia lingua, plantain seed, lophatherum gracile, agilawood, white paeony root and honey-fried licorice root according to a prescription, respectively carrying out microwave low-temperature drying and dehydration to ensure that the water content of the traditional Chinese medicine is below 5%, respectively powdering by a low-temperature wall breaking machine to prepare traditional Chinese medicine superfine powder with the cell wall breaking rate of above 95% and the powder particle diameter of below 5 mu m, uniformly mixing to prepare a traditional Chinese medicine composition, and adding 30mL of distilled water to prepare a suspension of 0.2g/mL.
Example 4: pharmacodynamic test
The invention provides a traditional Chinese veterinary medicine composition with anti-inflammatory, analgesic and diuretic effects, and in order to prove the treatment effect, the inventor performs pharmacodynamic experiments by using a suspension prepared by the method provided in the example 3, and the research results are as follows:
1. anti-inflammatory action
1) Test materials
The concentration of the veterinary drug composition suspension prepared in the example 3 of the invention is 0.2g/mL.
2) Test method
Healthy SPF-class Kunming mice, weighing 25+ -2 g, were taken 18 at 4 weeks of age, randomly divided into 3 groups of 6, male and female halves. Respectively negative controlDistilled water), positive control (2.5 mg/mL indomethacin), experimental (0.2 g/mL veterinary drug composition). After 3 days of adaptive feeding, the medicine is administrated by stomach irrigation, once daily, 0.2mL each time, and 3 days continuously. After 30min of last administration, 50 μl of xylene was uniformly applied to both front and back surfaces of auricles of right ear of each mouse, and left ear was used as a control. After 30min of inflammation, the cervical dislocation of the mice is killed, two ears are cut off along the auricle baseline, round ear pieces are punched on the same parts of the two ears by a puncher with the diameter of 6mm, and the mice are accurately weighed on a precision electronic balance of ten thousandth. The degree of swelling is expressed as the difference between the weights of the left and right ears, and the intensity of the anti-inflammatory effect is expressed as the inhibition ratio. Degree of swelling (mg) =weight of antiinflammatory side ear (mg) -weight of non-inflammatory side ear (mg), inhibition ratio (%) = (average degree of swelling of negative control group-average degree of swelling of administration group)/average degree of swelling of negative control group×100%. For experimental dataThe experimental results were shown to be processed using SPSS 26.0 statistical software. Comparison between groups uses a one-way analysis of variance, wherein the variance is normalized by LSD and the variance is normalized by Dunnett's T 3 The method tests that P <0.05 indicates that there is a significant difference. The specific results are shown in Table 1.
TABLE 1 influence of paraxylene-induced auricle swelling in mice for different pharmaceutical preparationsn＝6)
Note that: * Representing P <0.05 for each dosing group compared to the negative control group. Delta represents P >0.05 in the experimental group compared to the positive control group.
As can be seen from table 1, the auricle swelling degree of the positive control group and the experimental group was significantly lower than that of the negative control group, and the difference was significant (P < 0.05). The auricle swelling degree of the experimental group was not significantly different from that of the positive control group (P > 0.05).
The results show that the positive control group and the experimental group have obvious inhibition effect on the ear swelling of mice caused by the dimethylbenzene, and the veterinary drug composition in the experimental group has equivalent effect to the positive control drug, so that the veterinary drug composition has obvious anti-inflammatory effect.
2. Analgesic effect
2.1 Effect of different pharmaceutical preparations on the pain threshold of mice on thermal stimulation
1) Test materials
The concentration of the veterinary drug composition suspension prepared in the example 3 of the invention is 0.2g/mL.
2) Test method
Healthy female SPF-grade Kunming mice, 4 weeks old, weighing 25+ -2 g, were acclimatized for 3 days. The basic pain threshold of the mice on a hot plate at 55.0+/-0.5 ℃ is measured by using an intelligent hot plate instrument, namely the time required for the mice to lick the feet is repeated for 3 times, each time is divided into 5 minutes, the average number is calculated, 18 mice with the basic pain threshold between 5s and 30s and without jumping reaction are selected, and the mice are divided into 3 groups at random, and 6 mice in each group. Respectively negative control group (distilled water), positive control group (2.5 mg/mL indomethacin), and experimental group (0.2 g/mL veterinary drug composition). The medicine is administrated by stomach irrigation, once a day, with 0.2mL each time, and for 3 days continuously. The pain threshold of each mouse was measured on a 55.0.+ -. 0.5 ℃ hot plate using an intelligent hot plate instrument after 15min, 30min, 60min, 90min of the last administration, respectively, and the experiment was stopped if the pain threshold was 60s, and the mouse was taken out so as not to burn the sole of the mouse, and the pain threshold of the mouse was calculated as 60 s. The analgesic effect intensity is expressed as the pain threshold increase rate. Pain threshold increase (%) = (post-dose pain threshold-basal pain threshold)/basal pain threshold x 100%. For experimental dataThe experimental results were shown to be processed using SPSS 26.0 statistical software. Comparison between groups uses a one-way analysis of variance, wherein the variance is normalized by LSD and the variance is normalized by Dunnett's T 3 The method tests that P <0.05 indicates that there is a significant difference. The specific results are shown in Table 2.
TABLE 2 different pharmaceutical preparations for pain threshold to mice heat stimulusInfluence ofn＝6)
Note that: * Representing P <0.05 for each dosing group compared to the negative control group. The circle represents the experimental group compared with the positive control group, P <0.05, and the delta represents the experimental group compared with the positive control group, P >0.05.
As can be seen from Table 2, the pain threshold improvement rates of the positive control group and the experimental group are all obviously higher than those of the negative control group at 15min, 30min, 60min and 90min after the administration, and the difference is significant (P < 0.05). The pain threshold increase rate of the experimental group at 15min and 30min after the administration is smaller than that of the positive control group, and the difference is significant (P < 0.05). The pain threshold increase rate of the experimental group 60min after the administration was greater than that of the positive control group, and the difference was significant (P < 0.05). The pain threshold improvement rate of the experimental group 90min after administration was not significantly different from that of the positive control group (P > 0.05).
The results show that the positive control group and the experimental group can obviously improve the pain threshold of the thermal stimulation of the mice in different time periods after the administration, the effect of the positive control medicine is relatively more obvious compared with that of the veterinary medicine composition in the experimental group after the administration for 15min and 30min, but the effect of the veterinary medicine composition in the experimental group after the administration for 60min is more obvious compared with that of the positive control medicine, and the effect of the veterinary medicine composition in the experimental group after the administration for 90min is equivalent to that of the positive control medicine, so that the veterinary medicine composition has obvious analgesic effect and better long-acting analgesic effect.
2.2 Effect of different drug preparations on the writhing response of mouse acetic acid
1) Test materials
The concentration of the veterinary drug composition suspension prepared in the example 3 of the invention is 0.2g/mL.
2) Test method
Healthy SPF-class Kunming mice, weighing 25+ -2 g, were taken 18 at 4 weeks of age, randomly divided into 3 groups of 6, male and female halves. Respectively negative control group (distilled water), positive control group (2.5 mg/mL indomethacin), and experimental group (0.2 g/mL veterinary drug composition). After 3 days of adaptive feeding, the medicine is administrated by stomach irrigation, once daily, 0.2mL each time, and 3 days continuously. After the last administration for 30min, each mouse was intraperitoneally injected with 0.1ml/10g of 0.6% glacial acetic acid, and the time (latency) for which each mouse first developed torsion and the number of times of torsion of the mice within 20min were recorded. The analgesic effect intensity is expressed by the elongation rate and the analgesic rate. Elongation (%) = [ (dosing group latency-negative control group latency)/negative control group latency×100%. Analgesic rate (%) = (average number of twists of negative control group-average number of twists of administration group)/average number of twists of negative control group x 100%. For experimental dataThe experimental results were shown to be processed using SPSS 26.0 statistical software. Comparison between groups uses a one-way analysis of variance, wherein the variance is normalized by LSD and the variance is normalized by Dunnett's T 3 The method tests that P <0.05 indicates that there is a significant difference. The specific results are shown in Table 3.
TABLE 3 influence of different drug preparations on the acetic acid torsion reaction in micen＝6)
Note that: * Representing P <0.05 for each dosing group compared to the negative control group. The circle represents the experimental group compared with the positive control group, P <0.05, and the delta represents the experimental group compared with the positive control group, P >0.05.
As shown in Table 3, the number of twists and the incubation period of each administration group were significantly different (P < 0.05) compared with the negative control group, indicating that the modeling was successful. The latency of the experimental group was not significantly different from that of the positive control group (P > 0.05). The number of twists of the experimental group was significantly different from that of the positive control group (P < 0.05).
The results show that the positive control group and the experimental group can obviously prolong the incubation period of the acetic acid torsion of the mice and obviously reduce the frequency of acetic acid torsion reaction of the mice, and the effect of the veterinary drug composition in the experimental group on reducing the frequency of the acetic acid torsion of the mice is relatively more obvious compared with the effect of the veterinary drug composition in the experimental group on prolonging the incubation period of the mice, but the veterinary drug composition in the experimental group and the positive control drug are equivalent in effect, so that the veterinary drug composition has obvious analgesic effect.
3. Diuretic effect
1) Test materials
The concentration of the veterinary drug composition suspension prepared in the example 3 of the invention is 0.2g/mL.
2) Test method
Several healthy SPF-class Kunming mice with the weight of 25+/-2 g are taken to be 4 weeks old, placed in a metabolism cage of the mice and adaptively bred for 3 days, and screened after free water and food consumption and stable urine volume of the mice are obtained. The mice are fasted for 12 hours before screening, water is not forbidden, the lower abdomen of the mice is lightly pressed before operation, residual urine is drained, distilled water is added according to the gastric lavage of 0.2mL/10g, urine of 2 hours is collected, 18 mice with urine volume exceeding 40% of the dosage are selected to be incorporated into a formal experiment, and the mice are randomly divided into 3 groups of 6 mice each, and the mice are female and male half. Respectively negative control group (distilled water), positive control group (2.5 mg/mL hydrochlorothiazide), and experimental group (0.2 g/mL veterinary drug composition). The medicine is administrated by stomach irrigation, once a day, with 0.2mL each time, and for 3 days continuously. The animals are lightly pressed against the lower abdomen before the experiment and the residual urine is discharged after the last administration for 12 hours without water control, and each mouse is immediately administrated by stomach irrigation after intraperitoneal injection of 0.2mL/10g of physiological saline. Urine amounts of the mice were measured 1h, 2h, 3h, 4h, 5h, 6h, and 24h after the last administration, and recorded, and urine amounts per kg body weight were calculated. For experimental dataThe experimental results were shown to be processed using SPSS 26.0 statistical software. Comparison between groups uses one-way analysis of varianceWherein the variance is equal by LSD method and the variance is unequal by Dunnett's T 3 The method tests that P <0.05 indicates that there is a significant difference. The specific results are shown in Table 4.
TABLE 4 diuretic effect of different drug preparations on micen＝6)
Note that: * Representing P <0.05 for each dosing group compared to the negative control group. The circle represents the experimental group compared with the positive control group, P <0.05, and the delta represents the experimental group compared with the positive control group, P >0.05.
As can be seen from Table 4, the urine amounts of the positive control group and the experimental group in different time periods after administration are obviously larger than those of the negative control group, which proves that the experimental modeling is successful. Except for 2 hours after dosing, the difference in urine between the experimental and positive control groups was significant (P < 0.05), and the difference between the experimental and positive control groups was not significant (P > 0.05) for the rest of the time period.
The results show that the positive control group and the experimental group can both be used for controlling the urine volume of mice in different time periods after administration, and the animal medicine composition in the experimental group has the same effect as the positive control medicine, which indicates that the animal medicine composition in the invention has obvious diuretic effect.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.

Claims (3)

1. The veterinary Chinese medicine composition for treating cat stranguria is characterized by comprising the following components in percentage by weight: pyrrosia lingua 20 parts, plantain seed 20 parts and lophatherum gracile 20 parts
20 parts of agilawood, 20 parts of radix paeoniae alba and 20 parts of honey-fried licorice root
The preparation method comprises the following steps:
1) Drying folium Pyrrosiae at low temperature with microwave to remove water to water content below 5%, pulverizing into superfine powder with cell wall breaking rate above 95% and powder particle diameter below 5 μm;
2) Taking semen plantaginis, drying and dehydrating at low temperature by microwave to make the water content of the Chinese medicinal materials below 5%, pulverizing into powder with low temperature wall breaking machine to make the powder into Chinese medicinal superfine powder with cell wall breaking rate above 95% and powder particle diameter below 5 μm;
3) Drying herba Lophatheri at low temperature with microwave to remove water to make water content of Chinese medicinal materials below 5%, pulverizing with low temperature wall breaking machine to obtain superfine powder with cell wall breaking rate above 95% and powder particle diameter below 5 μm;
4) Drying lignum Aquilariae Resinatum with microwave at low temperature, dehydrating to water content of below 5%, pulverizing with low temperature wall breaking machine to obtain superfine powder with cell wall breaking rate of above 95% and powder particle diameter of below 5 μm;
5) Taking white peony root, drying and dehydrating at a low temperature by microwaves to ensure that the water content of the traditional Chinese medicine is below 5%, pulverizing the traditional Chinese medicine into powder by a low-temperature wall breaking machine to ensure that the cell wall breaking rate is above 95%, and preparing the traditional Chinese medicine superfine powder with the powder particle size below 5 mu m for later use;
6) Drying radix Glycyrrhizae Preparata with microwave at low temperature, dehydrating to water content below 5%, pulverizing with low temperature wall breaking machine to obtain superfine powder with cell wall breaking rate above 95% and powder particle diameter below 5 μm;
7) Mixing the superfine powder of the six Chinese medicinal materials obtained in 1), 2), 3), 4), 5) and 6), and making into oral medicine;
the oral medicine is powder and capsule.
2. The veterinary composition according to claim 1, wherein the oral powder is prepared by the following method: taking 120 parts of the prepared traditional Chinese veterinary medicine composition, further grinding, stirring and uniformly mixing by a small electric pulverizer, dividing into 10 bags, wherein each bag contains 12 parts of the traditional Chinese veterinary medicine composition, and packaging by hot-pressing plastic package.
3. The veterinary composition for treating cat stranguria according to claim 1, wherein the oral capsule is prepared by the following method: taking 300 parts of the prepared traditional Chinese veterinary medicine composition, further grinding, stirring and uniformly mixing by a small electric pulverizer, using a 100-hole No. 0 capsule plate, averagely subpackaging the traditional Chinese veterinary medicine composition into 100 No. 0 capsule bodies, wherein each granule contains 3 parts of the traditional Chinese veterinary medicine composition, and covering a capsule cap.
CN202211326301.4A 2022-10-25 2022-10-25 Traditional Chinese veterinary medicine composition for treating cat stranguria Active CN115518133B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211326301.4A CN115518133B (en) 2022-10-25 2022-10-25 Traditional Chinese veterinary medicine composition for treating cat stranguria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211326301.4A CN115518133B (en) 2022-10-25 2022-10-25 Traditional Chinese veterinary medicine composition for treating cat stranguria

Publications (2)

Publication Number Publication Date
CN115518133A CN115518133A (en) 2022-12-27
CN115518133B true CN115518133B (en) 2023-07-25

Family

ID=84703665

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211326301.4A Active CN115518133B (en) 2022-10-25 2022-10-25 Traditional Chinese veterinary medicine composition for treating cat stranguria

Country Status (1)

Country Link
CN (1) CN115518133B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1679692A (en) * 2005-02-03 2005-10-12 李浪辉 Medicine for gonorrhea and its preparation
CN103860695A (en) * 2014-02-27 2014-06-18 广西壮族自治区中医药研究院 Traditional Chinese medicine (TCM) composition for treating syndrome of dampness-heat in lower jiao caused by stranguria, and preparation method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102949607A (en) * 2011-08-31 2013-03-06 施瑞客（天津）生物技术有限公司 Traditional Chinese medicine composition for treating haematuria of cats

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1679692A (en) * 2005-02-03 2005-10-12 李浪辉 Medicine for gonorrhea and its preparation
CN103860695A (en) * 2014-02-27 2014-06-18 广西壮族自治区中医药研究院 Traditional Chinese medicine (TCM) composition for treating syndrome of dampness-heat in lower jiao caused by stranguria, and preparation method

Also Published As

Publication number Publication date
CN115518133A (en) 2022-12-27

Similar Documents

Publication Publication Date Title
CN102178103B (en) Suckling pig feed and preparation method thereof
CN100428950C (en) Medicine for preventing and treating chicken kidney swelling disease
CN102579597B (en) Chinese herbal compound prescription for preventing and curing mammitis of mammalian livestock and method for preparing same
CN115518133B (en) Traditional Chinese veterinary medicine composition for treating cat stranguria
CN102247570A (en) Traditional Chinese medicine composition for treating cow ketosis
CN105434915A (en) Pharmaceutical composition for treating urolithiasis for dogs and cats and preparation method of pharmaceutical composition
CN101218976A (en) Health food for improving sleeping and its preparation
CN110882345B (en) Traditional Chinese medicine composition for preventing and treating postpartum abdominal pain of dairy cows and preparation method thereof
CN1824204A (en) Medicinal composition for treating acute urarthritis and its preparation method
CN100455317C (en) Medicament for treating type 2 diabetes
CN102648746A (en) Diet fiber composition with intestine-nourishing constipation-releving functions
CN102335362B (en) Traditional Chinese medicine for treating insulin resistance of type 2 diabetes
CN103599281B (en) Traditional Chinese medicinal composition for treating obsessive-compulsive disorder and application thereof
CN101524447A (en) Pharmaceutical composition for treating constipation and preparation process thereof
CN1251751C (en) Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis
CN1069054C (en) Medicine for external use for curing chronic prostatitis
CN115607632A (en) A veterinary Chinese medicinal composition with antiinflammatory, analgesic and diuretic effects
CN1186052C (en) Medicine for treatment of pelvic inflammation, its preparation and preparing method
CN1301728C (en) Chinese medicine compound preparation for treating osteoarthropathy and its preparation method
CN115779046B (en) Traditional Chinese medicine composition, traditional Chinese medicine preparation and application for preventing and treating diabetes
CN115845003B (en) Application of traditional Chinese medicine composition in preparation of medicine for treating arthritis
CN101757369A (en) Medicine composition for treating acute goutry arthritis and preparation process thereof
CN101623468B (en) Medicine composition used for treating infection diseases of urinary system
CN117159655A (en) Cat soup capable of promoting urination and removing urinary calculus and preparation method of cat soup
CN118750535A (en) Traditional Chinese medicine composition for treating or preventing diarrhea type irritable bowel syndrome and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant